MONTBLANC (CBPD952A2309) phase II study: A 24-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

PROTECT (CM9S50802) An open-label, multicenter, phase II study assessing the safety of lucentis (ranibizumab) administered in conjunction with photodynamic therapy with visudyne in patients with occult or predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration

RESOLVE (B002D2201) A multicenter phase III trial assessing the efficacy and safety of intravitreal ranibizumab in patients with diabetic macular edema. 

MARAN, (Macula-relocation in exudative AMD) Comparative, randomized trial evaluating macula relocation in patients with subfoveal exudative AMD 

POOL, phase III study TIME (IVTA vs. ERM peeling in persistent macular edema) An open-label, multicenter, phase 4 study of the effect of visudyne therapy in subjects with occult with no classic choroidal neovascularization secondary to age-related macular degeneration 

MOLECULAR PARTNERS (MP0112-CP01), phase I and II study: An open-Label, multicenter, dose escalation study evaluating the safety and pharmacokinetic profile of intravitreal administered MP0112 in pateints with exudative age-related macular degeneration

CAIN (457C2301-3) A phase III , 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy

PATHALOGIC MYOPIA (CRFB002F2301) A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia

REACH (Eudract Number 2011-002526-43) A phase II study, single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration

REVEAL (CRFB002D2303) A randomized, double-masked, multicenter, laser controlled phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema

ALCON (C13001), phase II prospective, two cohort, single-masked study to evaluate the effect of ESBA1008 applied by microvolume injection or infusion in subjects with exudative age-related macular degeneration

DREAM (BAY 73-4506 / 15984) A combined phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age-related macular degeneration

DRAGON (CRFB002A2413)  Phase III study, 24-month, randomized, double-masked, controlled, multicenter study evaluating the efficacy and safety of ranibizumab 0.5 mg administered as two alternative dosing regimens in chinese patients with neovascular age-related macular degeneration

MINERVA (CRFB002G2301) A phase III study 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)

PROMETHEUS (CRFB002G2302) A phase III 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME)

EXPAND (CBAF312A2304), Phase III multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312

REFINE (CRFB002D2305) A phase III study, 12-month, randomized, double-masked, multicenter, laser-controlled phase III study assessing the efficacy and safety of 0.5 mg ranibizumab dosed PRN in subjects with visual impairment due to diabetic macular edema in chinese patients

FLUID (CRFB002AAU15) A phase IV, randomised, controlled, single masked study investigating the efficacy and safety of ranibizumab “inject and extend” using an intensive retinal fluid retreatment regimen compared to a relaxed retinal fluid retreatment regimen in patients with wet age-related macular degeneration (AMD).

RIVAL (CRFB002AAU17) A phase IV study: development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept

START STUDY A phase IV study for the assessment of early changes in SD-OCT after initiation of a treatment by intravitreal aflibercept (EYLEA®) (2mg) over a 12-week period for patients suffering from neovascular age-related macular degeneration (AMD) french SD OCT in wAMD.

NEMO (NRAS melanoma and MEK inhibitor) A randomized phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unrespectable or metastatic NRAS mutation-positive melanoma

DX211 (OCULIS ehf) A phase IIb study on efficacy and safety of dexamethasone nanoparticles eye drops in diabetic macular edema

ARIES (BAY86-5321/17508) A phase IV/IIIb study managing neovascular age-related macular degeneration (nAMD) over 2 years with a treat and extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study

CENTERA (BAY86--5321/17514) A multi-center, single-arm, interventional phase 4 study to evaluate a treat and extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion

OCRELIZUMAB (WA25046) A phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive multiple sclerosis

OCRELIZUMAB (WA21092, WA21093) A phase III randomized, double-blinded, double dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis

TONE (EudraCt No.: 2013-002515-10) A phase III study for treatment of optic neuritis with erythropoietin: a randomised, double-blind, placebo-controlled trial; TONE (P000053)